These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25073003)

  • 1. Prostate cancer: is androgen-deprivation therapy chosen wisely?
    Villanueva MT
    Nat Rev Clin Oncol; 2014 Sep; 11(9):501. PubMed ID: 25073003
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary androgen deprivation therapy in men with prostate cancer.
    Laufman L
    JAMA; 2009 Jan; 301(1):35; author reply 35. PubMed ID: 19126809
    [No Abstract]   [Full Text] [Related]  

  • 3. Measuring the effectiveness of androgen-deprivation therapy for prostate cancer in the medicare population: adequate data are neither the same as nor the enemy of perfect data.
    Trinh QD; Schrag D
    JAMA Intern Med; 2014 Sep; 174(9):1468-9. PubMed ID: 25023522
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate cancer: Say no to ADT for localized disease.
    Payton S
    Nat Rev Urol; 2014 Sep; 11(9):487. PubMed ID: 25069734
    [No Abstract]   [Full Text] [Related]  

  • 5. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
    Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
    Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone therapy in advanced prostate cancer.
    Forster TH; Stoffel F; Gasser TC
    Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
    [No Abstract]   [Full Text] [Related]  

  • 8. Survival following primary androgen deprivation therapy among men with localized prostate cancer.
    Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
    JAMA; 2008 Jul; 300(2):173-81. PubMed ID: 18612114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 10. Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma.
    Gibbs SJ; Plowman PN
    Clin Oncol (R Coll Radiol); 1996; 8(6):346-52. PubMed ID: 8973848
    [No Abstract]   [Full Text] [Related]  

  • 11. Hormonal therapies: ADT for prostate cancer: true love or heartbreak?
    Efstathiou JA; Shipley WU; Zietman AL; Smith MR
    Nat Rev Clin Oncol; 2010 Mar; 7(3):130-2. PubMed ID: 20190794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer: Why statins are beneficial.
    Thoma C
    Nat Rev Urol; 2015 Jul; 12(7):360. PubMed ID: 26032545
    [No Abstract]   [Full Text] [Related]  

  • 13. Intermittent androgen suppression. Too good to be true?
    Abrahamsson PA
    Scand J Urol Nephrol Suppl; 1999; 203():45-9. PubMed ID: 10636570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in Understanding What Is Being Statin(ed) in Prostate Cancer.
    Ramos JD; Yu EY
    JAMA Oncol; 2015 Jul; 1(4):428-30. PubMed ID: 26181247
    [No Abstract]   [Full Text] [Related]  

  • 15. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.
    Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
    JAMA Intern Med; 2014 Sep; 174(9):1460-7. PubMed ID: 25023796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine therapy of prostate cancer.
    Bare RL; Torti FM
    Cancer Treat Res; 1998; 94():69-87. PubMed ID: 9587683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
    Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
    Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and prospects of androgen depletion therapy for prostate cancer.
    Akaza H
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormone refractory prostate cancer and the prevention of the adverse effects of the treatment].
    Zgliczyński S; Borówka A
    Endokrynol Pol; 2005; 56(3):223. PubMed ID: 16350713
    [No Abstract]   [Full Text] [Related]  

  • 20. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
    Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
    Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.